Michael Brada FRCP FRCR DSc is a Professor of Radiation Oncology at the University of Liverpool; previously Professor of Clinical Oncology at ICR and the Royal Marsden Hospital, London. He is a leading international expert in neuro-oncology and thoracic oncology.
He published benchmark studies of technical aspects and clinical outcome of stereotactic radiotherapy and key studies of late toxicity of cranial irradiation. Has been involved in the evaluation of chemotherapy and radiotherapy in glial tumours including initial studies of Temozolomide. In the last decade the principal focus has been on lung cancer, developing and testing novel technologies including motion management techniques and high precision irradiation. Throughout his career he had a deep interest in improving methods of care and follow-up of cancer patients with studies resulting in changes to clinical practice.
He is also involved in evaluation of technologies through systematic reviews and meta-analyses, which have not infrequently generated heated debates. Authored and coauthored more than 250 peer-reviewed articles, editorials, and book chapters and countless abstracts and invited lectures at national and international conferences and meetings.
He served as the President of ESTRO (2003-2005), the President of the European Association of Neuro-oncology (EANO) and General Secretary of FECS (ECCO). He was the Chairman of the NCRI Brain Tumour CSG. Has been elected an honorary member of a number of national radiation oncology societies and a founding Fellow of European Academy of Cancer Sciences.